Skip to content

John H. Krystal

Yale University, VA Connecticut Healthcare System

60 papers in the library · 9,385 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.

Neuropsychopharmacology September 2008 Deepak Cyril D'Souza, Mohini Ranganathan, Gabriel Braley et al.

Cannabis is one of the most widely used illicit substances and there is growing interest in the association between cannabis use and psychosis. Delta-9-Tetrahydrocannabinol (Delta-9-THC) the principal active ingredient of cannabis has been shown to induce psychotomimetic and amnestic effects in healthy individuals. Whether people who frequently use cannabis are either protected from or are...

Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine

Archives of General Psychiatry September 1, 2005 John H. Krystal, Edward Perry, Ralitza Gueorguieva et al. 323 citations

BACKGROUND: In healthy individuals, ketamine hydrochloride and amphetamine sulfate produce cognitive, behavioral, and subjective effects resembling endogenous psychoses. Studying the comparative and interactive effects of these agents may provide insights into the roles of the glutamate and monoamine systems in psychosis and cognition. OBJECTIVES: To directly compare the effects of ketamine and...

Altered NMDA Glutamate Receptor Antagonist Response in Individuals With a Family Vulnerability to Alcoholism

American Journal of Psychiatry October 1, 2004 Ismene L. Petrakis, Diana Limoncelli, Ralitza Gueorguieva et al. 143 citations

OBJECTIVE: A family history of alcoholism is a risk factor for the development of ethanol dependence. Ethanol is an antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, and alterations in NMDA receptor function are thought to be involved in ethanol abuse and dependence. The purpose of this study was to determine in healthy individuals with no ethanol dependence whether response to...

DOI: 10.1176/ajp.161.10.1776 (opens in new tab) Nmda receptor Glutamate receptor Antagonist Vulnerability computing +2

NMDA receptor regulation of memory and behavior in humans

Hippocampus October 1, 2001 John W. Newcomer, John H. Krystal 238 citations

N-methyl-D-aspartate (NMDA) receptor hypofunction is associated with a range of effects on cognition and behavior in whole animal and human studies. NMDA receptor hypofunction within the brain, which can be induced experimentally in vivo using NMDA receptor antagonist drugs, produces adverse effects on memory function. The results suggest that NMDA receptor hypofunction can preferentially...

DOI: 10.1002/hipo.1069 (opens in new tab) Nmda receptor Memory consolidation Glutamate receptor Hippocampus

Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine

Archives of General Psychiatry March 1, 2000 Amit Anand, Dennis S. Charney, Dan A. Oren et al. 425 citations

BACKGROUND: The cognitive, behavioral, and mood effects of N-methyl-D-aspartate (NMDA) receptor antagonists, such as phencyclidine and ketamine, have been used to study the effects of NMDA receptor dysfunction. Pharmacological modulation of the effects of NMDA receptor antagonists, such as ketamine, may lead to development of novel therapeutic agents for psychiatric illnesses such as...

Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation.

October 1, 1999 R. Andrew Chambers, J. Douglas Bremner, Bita Moghaddam et al. 140 citations

Dissociative cognitive and perceptual alterations commonly occur at the time of traumatization and as an enduring feature of post-traumatic stress disorder (PTSD). After stress exposure, dissociative symptoms are a predictor of the development of PTSD. Recent preclinical data suggest that stress stimulates the cortico-limbic release of glutamate. The glutamate that is released during stress in...

DOI: 10.153/scnp00400274 (opens in new tab) Ketamine Nmda receptor Glutamate receptor Dissociative +3

The NMDA antagonist model for schizophrenia: promise and pitfalls.

Pharmacopsychiatry July 1, 1998 Walid Abi‐saab, Deepak C D'Souza, Bita Moghaddam et al.

Drug models have been extensively used to study the pathophysiology of schizophrenia. While they provide good insight into the neurobiology of this disorder, they have several shortcomings, which if known, help in the interpretation of results. In this paper we will discuss these shortcomings in general, and in relation to the N-methyl D-aspartate antagonist model for schizophrenia. This model...

Measurement of dissociative states with the Clinician‐Administered Dissociative States Scale (CADSS)

Journal of Traumatic Stress 1998 J. Douglas Bremner, John H. Krystal, Frank W. Putnam et al. 826 citations

The purpose of this study was to develop an instrument for the measurement of present-state dissociative symptoms, the Clinician Administered Dissociative States Scale (CADSS). Reported here are interrater reliability and internal consistency of the CADSS, validity as assessed by comparisons with other instruments for the assessment of dissociation, and sensitivity of the CADSS to discriminate...

DOI: 10.1023/a:1024465317902 (opens in new tab) Dissociative disorders Inter-rater reliability Dissociation chemistry Construct validity +8

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans

Archives of General Psychiatry March 1, 1994 John H. Krystal 3,339 citations

BACKGROUND: To characterize further behavioral, cognitive, neuroendocrine, and physiological effects of subanesthetic doses of ketamine hydrochloride in healthy human subjects. Ketamine, a phencyclidine hydrochloride derivative, is a dissociative anesthetic and a noncompetitive antagonist of the N-methyl-D-aspartate subtype of excitatory amino acid receptor. METHODS: Nineteen healthy subjects...

Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function?

The American Journal of Drug and Alcohol Abuse 1992 John H. Krystal, Lawrence H. Price, Charles Opsahl et al. 171 citations

3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a selective serotonin (5-HT) neurotoxin in animals. There is now preliminary evidence in humans of 5-HT deficits associated with extensive use of MDMA. In order to begin to describe the cognitive and mood effects of chronic MDMA use, nine individuals with extensive MDMA use histories were studied. Despite the absence of memory deficits on...